MedTrace Logo

Study of Erythropoietin (EPO) Administration Schedule

NCT01111630 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-05-14

No results posted yet for this study

Summary

The purpose of this study is to compare the hemoglobin and hematocrit variability between once and three times weekly erythropoietin therapy for the anemia in patients with maintenance dialysis.

Conditions

  • Chronic Renal Failure
  • Anaemia

Interventions

DRUG

recomon (Epoetin Beta)

administer once weekly

DRUG

recomon (Epoetin Beta)

administer three times weekly

Sponsors & Collaborators

Principal Investigators

  • SugKyun Shin, Ph.D. · National Health Insurance Service Ilsan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2013-10-31
Completion
2014-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01111630 on ClinicalTrials.gov